FARMAKOTERAPIYa VESTIBULYaRNOGO GOLOVOKRUZhENIYa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents a review of modern methods of medical treatment of acute and chronic vestibular vertigo. The role of pharmacotherapy of the most common diseases of the vestibular system, such as benign paroxysmal positional vertigo, Meniere's disease, vestibular neuronitis, migraine-associated vertigo, is discussed. The most effective approaches to the symptomatic and pathogenetic treatment of vestibular disorders are considered.

Full Text

Restricted Access

About the authors

M. V Zamergrad

Email: zamergrad@gmail.com

References

  1. Agrawal Y., Carey J.P., Della Santina C.C. Disorders of balance and vestibular function in US adults: data from the National Health and Nutrition Examination Survey, 2001-2004. Arch. Intern. Med. 2009; 169( 10):938-44.
  2. Neuhauser H.K., Lempert T. Vertigo: epidemiologic aspects. Semin. Neurol. 2009;29(5):473-81.
  3. Takeda N., Morita M., Hasegawa S., et al. Neurochemical mechanisms of motion sickness. Am. J. Otolaryngol. 1989;10:351-59.
  4. Storper I.S., Spitzer J.B., Scanlan M. Use of glycopyrrolate in the treatment of Meniere's disease. Laryngoscope. 1998; 108( 10): 1442-45.
  5. Brandt T. Vertigo. Its Multicensory Syndromes. London, 2000. 503 p.
  6. Rascol O., Hain T.C., Brefel C. Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs. 1995;50(5):777-91.
  7. Barone J.A. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann. Pharmacother. 1999; 33:429-40.
  8. Venail F., Biboulet R., Mondain M. A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: A pilot study. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2012; 129(2):65-8.
  9. Dominguez M.O. Treatment and rehabilitation in vestibular neuritis. Rev. Laryngol. Otol. Rhinol. (Bord). 2005; 126:283-86.
  10. Cass S.P., Borello-France D., Furman J.M. Functional outcome of vestibular rehabilitation in patients with abnormal sensory-organization testing. Am. J. Otol. 1996; 17:581-94.
  11. Krebs D.E., Gill-Body K.M., Parker S.W., et al. Vestibular rehabilitation: useful but not universally so. Otolaryngol. Head Neck Surg. 2003;128:240-50.
  12. Topuz O., Topuz B., Ardic F.N., et al. Efficacy of vestibular rehabilitation on chronic unilateral vestibular dysfunction. Clin. Rehabil. 2004;18:76-83.
  13. Mira E., Guidetti G., Ghilardi L., et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur. Arch. Otorhinolaryngol. 2003; 260: 73-7.
  14. Oosterveld W.J. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study. J. Laryngol. Otol. 1984; 98:37-41.
  15. Hamann K.F. Special ginkgo extract in cases of vertigo: a systematic review of randomised, double-blind, placebo controlled clinical examinations. HNO. 2007; 55:258-63.
  16. Orendors-Fraczkowska K., Pospiech L., Gawron W. Results of combined treatment for vestibular receptor impairment with physical therapy and Ginkgo biloba extract (Egb 761). Otolaryngol. Pol. 2002;56(1):83-8.
  17. Fernandes C.M., Samuel J. The use of piracetam in vertigo. S. Afr. Med. J. 1985; 68:806-08.
  18. Мельников О.А., Замерград М.В. Доброкачественное позиционное головокружение. Лечащий врач. 2000; 1:15-9.
  19. Herdman S.J. Treatment of benign paroxysmal vertigo. Phys. Ther. 1990;70;381-88.
  20. Korres S.G., Balatsouras D.G., Papouliakos S., Ferekidis E. Benign paroxysmal positional vertigo and its management. Med Sci Monit. 2007; 13:275-82.
  21. Пальчун В.Т., Кунельская Н.Л., Ротермел Е.В. Диагноз и лечение доброкачественного пароксизмального головокружения. Вест. оториноларингол. 2007;1:4-7.
  22. Guneri E.A., Kustutan O. The effects of betahistine in addition to epley maneuver in posterior canal benign paroxysmal positional vertigo. Otolaryngol. Head NeckSurg. 2012;146(1):104-08.
  23. Stambolieva K., Angov G. Effect of treatment with betahistine dihydrochloride on the postural stability in patients with different duration of benign paroxysmal positional vertigo. Int. Tinnitus J. 2010;16(1):32-6.
  24. Крюков А.И., Федорова О.К., Антонян Р.Г., Шеремет А.С. Клинические аспекты болезни Меньера. М., 2006. 239 с.
  25. Сагалович Б.М., Пальчун В.Т. Болезнь Меньера. М., 1999. 521 с.
  26. Gates G.A. Meniere's disease review 2005. J. Am. Acad. Audiol. 2006;17:16-6.
  27. Thirlwall A.S., Kundu S. Diuretics for Meniere's disease or syndrome. Cochrane Database Syst. Rev. 2006;19(3).
  28. Lezius F., Adrion C., Mansmann U., et al. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meniere's disease: a case series. Eur. Arch. Otorhinolaryngol. 2011;268(8):1237-40.
  29. Fishman J.M., Burgess C., Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst. Rev. 2011 ;11:5.
  30. Crevits L., Bosman T. Migraine-related vertigo: towards a distinctive entity. Clin. Neurol. Neurosurg. 2005;107:82-7.
  31. Eggers S.D. Migraine-related vertigo: diagnosis and treatment. Curr. Pain Headache Rep. 2007; 11:217-26.
  32. Carmona S., Bruera O. Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update. Ther. Clin. Risk Manag. 2009;5(3):661-69.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies